Inovio Pharmaceuticals (INO) to Release Quarterly Earnings on Wednesday

Inovio Pharmaceuticals (NASDAQ:INO) is expected to announce its earnings results before the market opens on Wednesday, March 5th. Analysts expect the company to post earnings of ($0.92) per share and revenue of $0.03 million for the quarter.

Inovio Pharmaceuticals Stock Down 7.1 %

Inovio Pharmaceuticals stock opened at $1.84 on Tuesday. Inovio Pharmaceuticals has a 52-week low of $1.74 and a 52-week high of $14.75. The firm has a market capitalization of $48.02 million, a price-to-earnings ratio of -0.88 and a beta of 0.89. The firm has a 50-day moving average price of $2.02 and a two-hundred day moving average price of $4.24.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on the company. JMP Securities reissued a “market outperform” rating and issued a $18.00 price objective on shares of Inovio Pharmaceuticals in a report on Friday, January 10th. Royal Bank of Canada decreased their price target on Inovio Pharmaceuticals from $7.00 to $6.00 and set a “sector perform” rating for the company in a research note on Friday, November 15th. HC Wainwright reduced their price objective on shares of Inovio Pharmaceuticals from $5.00 to $3.00 and set a “neutral” rating for the company in a report on Monday, January 13th. Finally, Oppenheimer lowered their target price on shares of Inovio Pharmaceuticals from $33.00 to $15.00 and set an “outperform” rating on the stock in a research note on Monday, November 18th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and three have assigned a buy rating to the stock. According to MarketBeat, Inovio Pharmaceuticals currently has an average rating of “Hold” and an average price target of $12.40.

Inovio Pharmaceuticals Company Profile

Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.